Evidence map›Paper›PMID 40439821›Full record

ArticleBreast cancer research and treatment2025

Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.

Arielle J Medford, Marko Velimirovic, Yifat Gefen, Andrzej Niemierko, Lorenzo Gerratana, Andrew A Davis, Katherine Clifton, Jennifer Keenan, Emily Podany, Whitney L Hensing and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Multidimensional roles and clinical significance of GATA3 in breast cancer.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Arielle J Medford *Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Marko Velimirovic *Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH, USA.
Yifat GefenCancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Andrzej NiemierkoMassachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Lorenzo GerratanaDepartment of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Andrew A DavisDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Katherine CliftonDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Jennifer KeenanMassachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Emily PodanyDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Whitney L HensingDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Carolina ReduzziWeill Cornell Medicine, 420 E 70 th St, LH 204, New York, NY, 10021, USA.
Charles S DaiMassachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Lesli A KiedrowskiDepartment of Medical Affairs, Guardant Health, Redwood City, CA, USA.
Laura M SpringMassachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Leif W EllisenMassachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Robert C DoebeleRain Therapeutics, Newark, CA, USA.
Massimo CristofanilliWeill Cornell Medicine, 420 E 70 th St, LH 204, New York, NY, 10021, USA.
Gad GetzMassachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Aditya BardiaDavid Geffen School of Medicine at UCLA & UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90024, USA. ABardia@mednet.ucla.edu.

Funding

Conquer Cancer Foundation ASCO Young Investigator Award
6 · The paper itself

Abstract

purposeGATA3 mutations are among the most common alterations in hormone receptor-positive (HR+) breast cancer (BC), yet these have no targeted therapies. MDM2 is an E3 ubiquitin ligase that targets p53 for degradation, and pre-clinical data suggests MDM2 inhibition may effectively treat GATA3 EXPERIMENTAL

designCirculating tumor DNA (ctDNA) was assessed for GATA3 mutations via targeted sequencing. Associations with co-alterations and clinical/pathologic factors were estimated using Pearson's chi-squared test, two-sample Wilcoxon rank-sum, and multivariable logistic regression. Impact on survival was analyzed using multivariable Cox regression analysis. Tissue-based data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database was evaluated for expression and phosphorylation of GATA3 and associated proteins.

resultsAmong 609 patients with HR + /HER2- MBC, ctDNA detected non-synonymous GATA3 variants ctDNA in 69 (11%) patients, and the genomic landscape was unique from tissue-based primary BC data; GATA3

conclusionThe distinct landscape in GATA3

Indexed as

Breast NeoplasmsGATA3 Transcription FactorMutationAdultAgedBiomarkers, TumorCirculating Tumor DNAErb-b2 Receptor Tyrosine KinasesFemaleGenomicsHumansMiddle AgedPrognosisProteomicsProto-Oncogene Proteins c-mdm2Receptors, EstrogenBiomarkers, TumorCirculating Tumor DNAErb-b2 Receptor Tyrosine KinasesGATA3 protein, humanGATA3 Transcription FactorMDM2 protein, humanProto-Oncogene Proteins c-mdm2Receptors, EstrogenReceptors, ProgesteroneBreast cancerCirculating tumor DNAGenomicsLiquid biopsy

Identifiers

PMID40439821
PMCPMC12209021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.